A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs GSK 3196165 (Primary) ; Folic acid; Methotrexate; Methotrexate
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 12 Jul 2017 Planned End Date changed from 6 Oct 2017 to 19 Oct 2017.
- 12 Jul 2017 Planned primary completion date changed from 1 May 2017 to 19 Oct 2017.
- 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.